🔗 Share this article

An senior health officer was taken off of oversight in an major clinical trial on hormone suppressants after claims of partiality surfaced.

Reported Involvement Led to Study Halt

Per media reports, Prof Jacob George, a chief scientific advisor for the medicines regulator, raised concerns which resulted in the pausing of the government-funded clinical study in early 2024.

The agency announced on Saturday that George had recused him from participation in the trial once questioning online posts posted in the past were identified.

Content of Online Posts

Among a post, George described author J.K. Rowling being an asset of this era.” Elsewhere, the professor stated how the rejection of fundamental biological fact is troubling” in regards to debates about an Olympic athlete’s gender.

The regulator clarified that while the comments were made prior to his official position, the official was removed from involvement with the study as an abundance of caution.

Details of the Halted Clinical Trial

This Pathways trial, that aimed to study the effect of puberty blockers for children uncertain about their gender, was due to begin recruiting participants during January.

Yet, the trial was suspended during February when its agency expressed concerns regarding the safety for adolescents taking part.

• Its youngest volunteers were expected to be 10 to 11 among girls while eleven to twelve among assigned male at birth.
• Its research leadership stated previously how the rigorous screening procedure indicated those enrolled would likely be of a higher age.
• But, the agency has now said the minimum age requirement ought to be fourteen owing to an uncertain potential” for enduring biological harms.”

This study had planned to include an estimated 226 young people over the following 36 months.

Context Following a Independent Report

This study was announced following an urging by the Cass review on children’s gender care, which concluded how the quality of research claiming to demonstrate the benefits of this type of medication for youngsters with gender dysphoria was weak.”

Dr Hilary Cass, who chaired the report, had earlier commented her report “uncovered a very weak body of research” for the usefulness of such treatments.

Dr. Cass added, “given that there are doctors, young people and parents who believe deeply of the positive outcomes, research was the only way ahead to make sense of this.”

Expert Concern of the Decision

Dr Max Davie, a consultant paediatrician, said there was no convincing medical rationale to halt the trial.

“The social media posts by Prof George provide a clear indication of his individual stance on this issue,” he stated. “The professor is entitled to hold any beliefs on this subject he wishes, but what is improper is allow these beliefs to affect the performance of his public duty.”

The doctor added: “For clarity, there is no definitive medical basis to halt the Pathways trial. While the professor’s personal convictions are not the only plausible cause for the regulator’s unexpected volte-face, it is the only one for which we have supporting information.”

Regulator Statement and Future Actions

A regulatory spokesperson stated: “With all clinical trials, our foremost duty is the protection and wellbeing for the trial participants. As part of this duty, detailed studies are kept continuously under review and the MHRA maintains a continuous conversation alongside trial sponsors.”

“The MHRA have world-class medical, scientific and regulatory specialists who function as a cross-functional group to provide research-informed rulings on medical research. These individuals shall persist to work with the university to address the next steps productively.”

“Subsequent to the finding of social media posts posted prior to his appointment, Prof Jacob George was recused of further oversight on the Pathways study as an preventative step.”